Owen Smith
Principal @ 4BIO Capital
London, United Kingdom
Owen Smith is a Series A investor at 4BIO Capital in London focused on Medical and Life Science. Owen Smith - Principal @ 4BIO Capital
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Owen Smith invests in
Stages Owen Smith invests in
Countries Owen Smith invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 3 (43%)
- Life Science 3 (43%)
- Biotechnology 3 (43%)
- Therapeutics 2 (29%)
- Biopharma 1 (14%)
Stage
- Series A 5 (71%)
- Series B 1 (14%)
- Funding Round 1 (14%)
Country
- United States 2 (29%)
- United Kingdom 2 (29%)
- France 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cytospire Therapeutics
|
Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M / Series A / May 05, 2026 | |
March Biosciences
|
March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M / Series A / Oct 23, 2024 | |
ViaNautis
|
Precision Solutions | $24.6M / Series A / Nov 13, 2023 | |
Entact Bio
|
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M / Series A / Dec 06, 2022 | |
SparingVision
|
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat allgenetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide. | $74.9M / Series B / Sep 14, 2022 | |
|
SparingVision
|
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat allgenetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide. | $48.8M / Oct 21, 2020 | |
|
SparingVision
|
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat allgenetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide. | $52.7M / Series A / Oct 21, 2020 |
Co-Investors
About 4BIO Capital
4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech -biologics, gene and cell therapy and bioinformatics.
4BIO Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Kozlov
Managing Partner
|
|||
Dmitry Kuzmin
Managing Partner
|
|||
Kieran Mudryy
Partner
|
|||
|
Owen Smith
Principal
|
|||
Vasily Fedorin
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Owen Smith invest in?
Owen Smith invests primarily in Medical, Life Science and Biotechnology startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Owen Smith?
Public channels for Owen Smith include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Owen Smith last invest?
The most recent investment recorded for Owen Smith closed in May 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
